Skip to main content
Fig. 2 | BMC Rheumatology

Fig. 2

From: Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study

Fig. 2

The Kaplan–Meier curves of the persistency rates and event-free survival rates of the two drugs

(A) The Kaplan–Meier curves of the persistency rate of the two drugs. (B) The Kaplan–Meier curves of the event-free survival of the two drugs

The persistency rates at 2 years after treatment initiation were 42.9% and 50.5% for ABT and JAKi, respectively. The event-free survival rates at 2 years after treatment initiation were 75.0% and 74.7%, respectively. There was no significant difference in the rates between the two groups (A, P = 0.256; B, P = 0.683)

JAKi: Janus kinase inhibitor; ABT: abatacept

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us